About Diagnostear
Diagnostear is a publicly listed company based in Tel Aviv (Israel) founded in 2013. A point-of-care diagnostic assay for dry eye syndrome is developed. Diagnostear has raised $2.85 million across 2 funding rounds from investors including Elcam Medical. Diagnostear offers products and services including TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector. Its focus areas include Life Sciences, Ophthalmology and In-Vitro Diagnostic Tests.
Company details
Diagnostear is focussed on developing a point of care diagnostic test for dry eye syndrome (DES). It has developed an assay test called TeaRx based on various reagents that create color reactions when comes in contact with tear film and then provides a multi-parameter semi-quantitative analysis to identify the underlying causes of DES. As of October 2016, the test is in clinical development has shown positive second clinical study results in January 2016. The company DiagnosTear is part of BioLights XLVision Sciences ophthalmology cluster.
- Headquarters Tel Aviv, Israel
- Stage Public
- SectorsHealthcare
- Website diagnostear.com
- Social LinkedIn
- Legal Name Diagnostear Technologies, Inc.
- Net Profit-$2.42 M (USD)79.25as on Dec 31, 2025
- EBITDA-$2.59 M (USD)-165.74as on Dec 31, 2025
- Total Equity Funding$2.85M (USD)
in 2 rounds
- Latest Funding Round$2.85M (USD), Series A
Oct 2020
- Investors
Products & Services of Diagnostear
Diagnostear offers a comprehensive portfolio of products and services, including TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector.
Test for identifying and monitoring Dry Eye Syndrome.
Assesses conditions like adenoviral conjunctivitis and allergic conjunctivitis.
Microfluidic device for collecting tear fluid samples.
Funding Insights of Diagnostear
Diagnostear has successfully raised a total of $2.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.85 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.85M
- Total Rounds 2
- Last Round Series A — $2.85M
- Investors Count 1
All 2 funding rounds of Diagnostear with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $2.85M | Series A | – | Elcam Medical | – |
| Oct 2015 | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Diagnostear
Diagnostear has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Elcam Medical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| elcam-medical.com |
Investor details for Diagnostear
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Diagnostear
Diagnostear is a publicly listed company on the CSE with ticker symbol DTR in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Dec 2024
- Listed onCSE: DTR
- Listed entityDiagnosTear Technologies, Inc.
- Exchange sectorHealth technology
- ISINCA25244H1055
- Share price0.29 CAD (+18.37% on the day) · 2026-10-13
- Market capitalisation17,585,117.00 CAD
- Volume (last session)20,500
Financials of Diagnostear
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -3.3M CAD | -3.5M CAD | |
| 2024 | -16.0M CAD | -1.3M CAD | |
| 2023 | -1.1M CAD | -1.1M CAD | |
| 2022 | -1.2M CAD | -1.0M CAD |
Detailed financial statements for Diagnostear
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Diagnostear
4 dated milestones of Diagnostear across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Diagnostear is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $2.9M.
- IPO Lists on the stock exchange (IPO).
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Diagnostear
Complete news archive for Diagnostear
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diagnostear
Diagnostear was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Diagnostear is headquartered in Tel Aviv, Israel.
Diagnostear is a funded company, having raised a total of $2.85M across 2 funding rounds to date.
Diagnostear is focussed on developing a point of care diagnostic test for dry eye syndrome (DES). It has developed an assay test called TeaRx based on various reagents that create color reactions when comes in contact with tear film and then provides a multi-parameter semi-quantitative analysis to identify the underlying causes of DES. As of October 2016, the test is in clinical development has shown positive second clinical study results in January 2016. The company DiagnosTear is part of BioLights XLVision Sciences ophthalmology cluster.
Diagnostear offers TeaRx Dry Eye, TeaRx Red Eye, and TeaRx Tear Collector.
Yes, Diagnostear is publicly traded on CSE under the ticker symbol DTR.
Diagnostear has 1 investor. Key investors include Elcam Medical.